On the stock market since 2020, it operates in the world of health and science. It has 667 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
No real growth (2% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
An investor who bought at the very peak is down 96% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $539.6M a year; the problem isn’t sales — it’s costs running above that number.
There is $481.4M in the vault; even if every debt were paid off, $438.2M would remain.
It met or beat analyst expectations in 6 of the last 6 quarters — consistency is a promise kept.
A loss of $55.3M against $539.6M in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, BNR sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: BNR has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.